U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07617493) titled 'Evaluation of ICP-B208 in Patients With Advanced Solid Tumors' on May 14.
Brief Summary: To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: ICP-B208
ICP-B208 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).
Recruitment Status: NOT_YET_RECRU...